Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INX-0167
- Development stage
- Preclinical
- Lead developer
- Inex Pharmaceuticals
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
INX-0167 is an immunostimulatory liposomal biologic formulation developed by INEX Pharmaceuticals. It consists of synthetic oligonucleotides encapsulated within a proprietary liposomal delivery system. The drug is designed to stimulate the immune system, specifically by increasing the number and activity of natural killer (NK) cells and T-lymphocytes. By boosting NK cell activity, INX-0167 enhances antibody-dependent cell-mediated cytotoxicity (ADCC), making it a potent candidate for combination therapy with monoclonal antibodies. Preclinical studies have demonstrated synergistic anti-tumor effects when combined with rituximab for B-cell lymphoma and trastuzumab for HER2-positive tumors.
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on INX-0167.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INX-0167.